NAMSNewAmsterdam Pharma Company N.V.
$18.97-50% 1Y
$18.97
$18.8752 weeks$41.45
The business
How NAMS's business earns
NewAmsterdam Pharma Company N.V. spent more than it took in: an operating loss of $233M on $26M of revenue, 12 months to Sep 30, 2026.
$233M
Operating loss · on $26M of revenue · 12 months to Sep 30, 2026
- Share count, year on year
- +4.3%
Share count, year on year · more shares than a year ago
Operating margin by fiscal year
| Year | Operating margin |
|---|---|
| FY2022 | −3.5% |
| FY2023 | −1299% |
| FY2024 | −387% |
| FY2025 | −1003% |
Details›
- Operating margin12 months to Sep 30, 2026
- −900%
- Net margin12 months to Sep 30, 2026
- −790%
- Free cash flow margin
- −582%
- R&D as % of revenue
- 608%
- Revenue, trailing twelve months
- $26M
- Free cash flow, trailing twelve months
- −$151M
- Net income, trailing twelve months
- −$205M
Margins, capital and share counts from the statements as filed with the SEC; cash conversion is operating cash flow over operating profit after tax.
Biotechnology
The closest names by size in the same industry